Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416 21. S7.1.1-13. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effec- tiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii iv, ix xi, 1 164 S7.1.1-14. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost- effectiveness of implantable cardioverter defibrillators in the treat- ment of ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002;112:519 27. S7.1.1-15. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. 7.1.1.1. Coronary Artery Spasm S7.1.1.1-1. Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol. 1998;31:57 61. S7.1.1.1-2. Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial isch- emia due to coronary-artery spasm. N Engl J Med. 1992;326: 1451 5. S7.1.1.1-3. Ahn JM, Lee KH, Yoo SY, et al. Prognosis of variant angina manifesting as aborted sudden cardiac death. J Am Coll Cardiol. 2016;68:137 45. S7.1.1.1-4. Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospas- tic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012;60:908 13. S7.1.1.1-5. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who sur- vived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association.


Clinical characteristics and long-term prognosis of vasospastic angina patients who sur- vived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295 302. S7.1.1.1-6. Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implant- able cardioverter-defibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiograph- ically normal coronary arteries. Am J Cardiol. 2002;89:1114 6. S7.1.1.1-7. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008). Circ J. 2010;74:1745 62. S7.1.1.1-8. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344 426. S7.1.1.1-9. Morikawa Y, Mizuno Y, Yasue H. Letter by Morikawa et al regard- ing article, coronary artery spasm: a 2009 update. Circulation. 2010;121:e16. S7.1.1.1-10. Sasaki S, Tomita H, Shibutani S, et al. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J. 2014;78:2987 9. 7.1.1.2. Post CABG VT/VF S7.1.1.2-1. Ascione R, Reeves BC, Santo K, et al. Predictors of new malig- nant ventricular arrhythmias after coronary surgery: a case-control study. J Am Coll Cardiol. 2004;43:1630 8. CLINICAL STATEMENTS AND GUIDELINES S7.1.1.2-2. Saxon LA, Wiener I, Natterson PD, et al. Monomorphic versus poly- morphic ventricular tachycardia after coronary artery bypass graft- ing. Am J Cardiol. 1995;75:403 5. S7.1.1.2-3. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric- ular tachycardia after cardiac surgery. Circulation. 1999;99:903 8. S7.1.1.2-4. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary- artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569 75. S7.1.1.2-5.


Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569 75. S7.1.1.2-5. Vakil K, Florea V, Koene R, et al. Effect of coronary artery bypass grafting on left ventricular ejection fraction in men eli- gible for implantable cardioverter-defibrillator. Am J Cardiol. 2016;117:957 60. S7.1.1.2-6. Mittal S, Lomnitz DJ, Mirchandani S, et al. Prognostic significance of nonsustained ventricular tachycardia after revascularization. J Cardiovasc Electrophysiol. 2002;13:342 6. S7.1.1.2-7. Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defi- brillator. Circ Arrhythm Electrophysiol. 2013;6:117 28. 7.1.2. Primary Prevention of SCD in Patients With Ischemic Heart Disease S7.1.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S7.1.2-2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877 83. S7.1.2-3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933 40. S7.1.2-4. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk strati- fication on cost-effectiveness of the implantable cardioverter defi- brillator. Am Heart J. 2002;144:440 8. S7.1.2-5. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre- vention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882 90. S7.1.2-6. Cantero-P rez EM, Sobrino-M rquez JM, Grande-Trillo A, et al. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart trans- plantation. Transplant Proc.


Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart trans- plantation. Transplant Proc. 2013;45:3659 61. S7.1.2-7. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158 65. S7.1.2-8. Gandjbakhch E, Rovani M, Varnous S, et al. Implantable cardio- verter-defibrillators in end-stage heart failure patients listed for heart transplantation: results from a large retrospective registry. Arch Cardiovasc Dis. 2016;109:476 85. S7.1.2-9. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio- verter-defibrillators on waitlist mortality among patients await- ing heart transplantation: an UNOS/OPTN analysis. JACC Clin Electrophysiol. 2017;3:33 40. S7.1.2-10. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarc- tion. N Engl J Med. 2004;351:2481 8. S7.1.2-11. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427 36. S7.1.2-12. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97:2129 35. S7.1.2-13. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310 8. S7.1.2-14. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi- brillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT). Circulation. 2006;114:135 42. S7.1.2-15. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco- nomic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593 600. S7.1.2-16. Buxton AE, Calkins H, Callans DJ, et al.


2005;142:593 600. S7.1.2-16. Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards. Circulation. 2006;114:2534 70. S7.1.2-17. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec- tiveness of prophylactic implantation of a cardioverter defibril- lator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716 26. S7.1.2-18. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implant- able cardioverter-defibrillators. N Engl J Med. 2005;353:1471 80. S7.1.2-19. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of pri- mary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34:211 9. S7.1.2-20. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S7.1.2-21. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic test- ing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342:1937 45. S7.1.2-22. Zaman S, Sivagangabalan G, Narayan A, et al. Outcomes of early risk stratification and targeted implantable cardioverter-defibrilla- tor implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2009;120:194 200. S7.1.2-23. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 50. S7.1.2-24. Kusumoto FM, Calkins H, Boehmer J, et al.


2004;350:2140 50. S7.1.2-24. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defi- brillator therapy in patients who are not included or not well rep- resented in clinical trials. Circulation. 2014;130:94 125. 7.1.3. Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease S7.1.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165 71. S7.1.3-2. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implant- able-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855 62. S7.1.3-3. Kettering K, Mewis C, Dornberger V, et al. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricu- lar tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2002;25:1571 6. S7.1.3-4. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia abla- tion versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111 21. S7.1.3-5. Mallidi J, Nadkarni GN, Berger RD, et al. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ven- tricular tachycardia in patients with structural heart disease. Heart Rhythm. 2011;8:503 10. S7.1.3-6. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricu- lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674 83. S7.1.3-7. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773 82. S7.1.3-8. Tanner H, Hindricks G, Volkmer M, et al.


2008;118:2773 82. S7.1.3-8. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recur- rent scar-related ventricular tachycardia using electroanatomical CLINICAL STATEMENTS AND GUIDELINES mapping and irrigated ablation technology: results of the pro- spective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21:47 53. S7.1.3-9. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997 2007. S7.1.3-10. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2015;26:151 7. S7.1.3-11. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre ran- domised controlled trial. Lancet. 2010;375:31 40. S7.1.3-12. Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. Heart Rhythm. 2007;4:1395 402. S7.1.3-13. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. S7.1.3-14. Sears SF Jr, Todaro JF, Lewis TS, et al. Examining the psychoso- cial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22:481 9. S7.1.3-15. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric- ular tachycardia after cardiac surgery. Circulation. 1999;99:903 8. S7.1.3-16. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revasculariza- tion in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol. 2001;37:529 33. S7.1.3-17. Claro JC, Candia R, Rada G, et al.


2001;37:529 33. S7.1.3-17. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.1.3-18. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ven- tricular tachycardia burden and ICD shocks in patients with drug- refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600 6. S7.1.3-19. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250 9. S7.1.3-20. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77 82. S7.1.3-21. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227 33. S7.1.3-22. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.1.3-23. Sears SE Jr, Conti JB, Understanding implantable cardioverter defi- brillator shocks and storms: medical and psychosocial consider- ations for research and clinical care. Clin Cardiol. 2003;26:107 11. S7.1.3-24. Sweeney MO, Sherfesee L, Degroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7:353 60. S7.1.3-25. Berntsen RF, Gunnes P, Lie M, et al. Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia. Eur Heart J. 1993;14:1297 303. S7.1.3-26. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/ SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016;32:1 28. 7.2. Nonischemic Cardiomyopathy S7.2-1.


2015 HRS/EHRA/APHRS/ SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016;32:1 28. 7.2. Nonischemic Cardiomyopathy S7.2-1. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501 11. S7.2-2. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhance- ment on cardiac magnetic resonance predicts adverse cardiovascu- lar outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250 8. S7.2-3. Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S7.2-4. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen- sus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partner- ship between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077 109. S7.2-5. Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12:655 67. S7.2-6. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016. 2017;10:411 20. S7.2-7. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.2-8. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68:2299 307. S7.2-9. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.2-10.


Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.2-10. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.2-11. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.2-12. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. 7.2.1. Secondary Prevention of SCD in Patients With NICM S7.2.1-1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S7.2.1-2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implant- able cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. S7.2.1-3. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardio- myopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874 9. S7.2.1-4. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.2.1-5. Raitt MH, Renfroe EG, Epstein AE, et al. Stable ventricular tachy- cardia is not a benign rhythm: insights from the Antiarrhythmics versus Implantable Defibrillators (AVID) registry. Circulation. 2001;103:244 52. S7.2.1-6. Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope.


Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol. 2001;24:1623 30. S7.2.1-7. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol. 2000;85:981 5. S7.2.1-8. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonisch- emic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964 70. CLINICAL STATEMENTS AND GUIDELINES S7.2.1-9. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of ori- gin of syncope. J Am Coll Cardiol. 1993;21:110 6. S7.2.1-10. Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the out- come of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol. 2008;51:1277 82. S7.2.1-11. Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk car- diomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inap- propriate therapy (MADIT-RIT) study. Circulation. 2014;129:545 52. S7.2.1-12. Piccini JP, Berger JS, O Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245 53. S7.2.1-13. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.2.1-14. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhyth- mia inducibility predicts subsequent ICD activation in nonisch- emic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755 61. S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al.


2009;32:755 61. S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stim- ulation. Circ Arrhythm Electrophysiol. 2013;6:504 12. S7.2.1-16. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro- physiological studies to predict arrhythmic events. World J Cardiol. 2015;7:344 50. S7.2.1-17. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mortal- ity. Am Heart J. 2008;155:87 93. 7.2.2. Primary Prevention of SCD in Patients With NICM S7.2.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S7.2.2-2. B nsch D, Antz M, Boczor S, et al. Primary prevention of sud- den cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453 8. S7.2.2-3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 50. S7.2.2-4. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardio- myopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874 9. S7.2.2-5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan- tation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151 8. S7.2.2-6. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic non- sustained ventricular tachycardia AMIOVIRT. J Am Coll Cardiol. 2003;41:1707 12. S7.2.2-7. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8.


Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.2.2-8. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.2.2-9. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.2.2-10. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation car- riers: a European cohort study. J Am Coll Cardiol. 2012;59: 493 500. S7.2.2-11. K ber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221 30. S7.2.2-12. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2:685 8. S7.2.2-13. Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defi- brillator for nonischemic cardiomyopathy: an updated meta-analy- sis. Circulation. 2017;135:201 3. 7.2.3. Treatment of Recurrent VA in Patients With NICM S7.2.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165 71. S7.2.3-2. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla- tion of ventricular tachycardia in dilated nonischemic cardiomy- opathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728 36. S7.2.3-3. Tung R, Vaseghi M, Frankel DS, et al.


2014;129:728 36. S7.2.3-3. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997 2007. S7.2.3-4. Piers SR, Tao Q, Tvan Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S7.2.3-5. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramu- ral scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2013;6:891 7. S7.2.3-6. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407 13. 7.3. Arrhythmogenic Right Ventricular Cardiomyopathy S7.3-1. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8:437 46. S7.3-2. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:1945 8. S7.3-3. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth- mogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701 9. S7.3-4. te Riele AS, James CA, Groeneweg JA, et al. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomy- opathy. Eur Heart J. 2016;37:755 63. S7.3-5. Liu T, Pursnani A, Sharma UC, et al. Effect of the 2010 task force criteria on reclassification of cardiovascular magnetic resonance criteria for arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:47. S7.3-6. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmo- genic right ventricular cardiomyopathy/dysplasia: proposed modifi- cation of the task force criteria. Circulation. 2010;121:1533 41.


Diagnosis of arrhythmo- genic right ventricular cardiomyopathy/dysplasia: proposed modifi- cation of the task force criteria. Circulation. 2010;121:1533 41. S7.3-7. te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratifica- tion of arrhythmogenic right ventricular dysplasia/cardiomyopa- thy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1761 9. S7.3-8. Vermes E, Strohm O, Otmani A, et al. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force criteria on its prevalence by CMR criteria. JACC Cardiovasc Imag. 2011;4:282 7. S7.3-9. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy under- going implantable cardioverter-defibrillator implantation for pri- mary prevention. J Am Coll Cardiol. 2011;58:1485 96. CLINICAL STATEMENTS AND GUIDELINES S7.3-10. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defi- brillator in patients with arrhythmogenic right ventricular cardiomy- opathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144 52. S7.3-11. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015;132:441 53. S7.3-12. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, charac- teristics, and treatment. J Am Coll Cardiol. 2014;64:119 25. S7.3-13. Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate implant- able defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2005;2:1188 94. S7.3-14. Marcus FI, Zareba W, Calkins H, et al. Arrhythmogenic right ventric- ular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm. 2009;6:984 92. S7.3-15. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhyth- mic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.


Efficacy of antiarrhyth- mic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009;54:609 15. S7.3-16. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopatho- logic manifestations of arrhythmogenic right ventricular car- diomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512 20. S7.3-17. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age- related penetrance and arrhythmic risk in arrhythmogenic right ven- tricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1290 7. S7.3-18. Ruwald AC, Marcus F, Estes NA 3rd, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015;36:1735 43. S7.3-19. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014;16:1337 44. S7.3-20. Sawant AC, Bhonsale A, te Riele AS, et al. Exercise has a dispropor- tionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal muta- tions. J Am Heart Assoc. 2014;3:e001471. S7.3-21. Sawant AC, te Riele AS, Tichnell C, et al. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016;13:199 207. S7.3-22. Bhonsale A, Groeneweg JA, James CA, et al. Impact of geno- type on clinical course in arrhythmogenic right ventricular dys- plasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36:847 55. S7.3-23. Bhonsale A, James CA, Tichnell C, et al. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associ- ated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013;6:569 78. S7.3-24. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua- tion of cardiomyopathy a Heart Failure Society of America practice guideline.


Genetic evalua- tion of cardiomyopathy a Heart Failure Society of America practice guideline. J Card Fail. 2009;15:83 97. S7.3-25. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associ- ated mutations from background genetic noise. J Am Coll Cardiol. 2011;57:2317 27. S7.3-26. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533 42. S7.3-27. Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dyspla- sia/cardiomyopathy. Heart Rhythm. 2015;12:716 25. S7.3-28. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ven- tricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5:499 505. S7.3-29. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter abla- tion of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:432 40. S7.3-30. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and out- come with epicardial ablation of ventricular tachycardia in arrhyth- mogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009;120:366 75. S7.3-31. Bai R, Di BL, Shivkumar K, et al. Ablation of ventricular arrhyth- mias in arrhythmogenic right ventricular dysplasia/cardiomyopa- thy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol. 2011;4: 478 85. S7.3-32. Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endo- cardial and epicardial catheter ablation in arrhythmogenic right ven- tricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5:111 21. S7.3-33. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413 21. S7.3-34. Choudhary N, Tompkins C, Polonsky B, et al.


2015;8:1413 21. S7.3-34. Choudhary N, Tompkins C, Polonsky B, et al. Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: findings from the North American ARVC Registry. J Cardiovasc Electrophysiol. 2016;27:555 62. S7.3-35. Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopa- thy/dysplasia. Heart Rhythm. 2011;8:256 62. S7.3-36. Saguner AM, Medeiros-Domingo A, Schwyzer MA, et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2013;111:250 7. S7.3-37. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhyth- mogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175 87. S7.3-38. Te Riele AS, James CA, Philips B, et al. Mutation-positive arrhyth- mogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013;24: 1311 20. S7.3-39. Rastegar N, Zimmerman SL, Te Riele AS, et al. Spectrum of biven- tricular involvement on cmr among carriers of arvd/c-associated mutations. JACC Cardiovasc Imag. 2015;8:863 4. S7.3-40. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic charac- terization of families with arrhythmogenic right ventricular dyspla- sia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710 20. S7.3-41. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricu- lar dysplasia: a United States experience. Circulation. 2005;112: 3823 32. S7.3-42. Brun F, Groeneweg JA, Gear K, et al. Risk stratification in arrhythmic right ventricular cardiomyopathy without implantable cardioverter- defibrillators. JACC Clin Electrophysiol. 2016;2:558 64. S7.3-43. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084 91. S7.3-44. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study.


Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. S7.3-45. Cox MG, van der Zwaag PA, van der Werf C, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmo- some mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/car- diomyopathy genotype-phenotype follow-up study. Circulation. 2011;123:2690 700. S7.3-46. Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro- physiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758 62. S7.3-47. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299 302. S7.3-48. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhyth- mic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29 37. CLINICAL STATEMENTS AND GUIDELINES 7.4. Hypertrophic Cardiomyopathy S7.4-1. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596 601. S7.4-2. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertro- phic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212 8. S7.4-3. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420 4. S7.4-4. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic car- diomyopathy. Eur Heart J. 2006;27:1933 41. S7.4-5. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774 8. S7.4-6. Maron BJ, Spirito P, Shen WK, et al.


1998;82:774 8. S7.4-6. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defi- brillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405 12. S7.4-7. O Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010 20. S7.4-8. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119:1703 10. S7.4-9. O Mahony C, Lambiase PD, Quarta G, et al. The long-term sur- vival and the risks and benefits of implantable cardioverter defi- brillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116 25. S7.4-10. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter- defibrillator in patients with hypertrophic cardiomyopathy: effi- cacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21:883 9. S7.4-11. Adabag AS, Kuskowski MA, Maron BJ. Determinants for clini- cal diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:1507 11. S7.4-12. Afonso LC, Bernal J, Bax JJ, et al. Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technolo- gies. JACC Cardiovasc Imag. 2008;1:787 800. S7.4-13. Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010;55:1444 53. S7.4-14. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972 7. S7.4-15. Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation. 2013;127:48 54. S7.4-16. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two- dimensional echocardiography in 600 patients.


Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two- dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699 708. S7.4-17. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic car- diomyopathy. Clinical spectrum and treatment. Circulation. 1995;92:1680 92. S7.4-18. Christiaans I, Birnie E, van Langen IM, et al. The yield of risk strati- fication for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predic- tive screening. Eur Heart J. 2010;31:842 8. S7.4-19. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic car- diomyopathy. Mayo Clin Proc. 2008;83:630 8. S7.4-20. Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients perspective. Am J Med Genet. 2009 149a 1444 51. S7.4-21. Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. J Genet Counsel. 2012;21:72 84. S7.4-22. Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype- based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727 37. S7.4-23. Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788 95. S7.4-24. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopa- thy. N Engl J Med. 2000;342:1778 85. S7.4-25. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.


Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481 6. S7.4-26. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardio- verter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365 73. S7.4-27. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricu- lar tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873 9. S7.4-28. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of sys- temic blood pressure response during exercise in a community- based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044 51. S7.4-29. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assess- ment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987 91. S7.4-30. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ven- tricular tachycardia. Br Heart J. 1985;53:412 6. S7.4-31. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hyper- trophic cardiomyopathy. Heart. 2007;93:708 10. S7.4-32. Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimu- lation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J. 1988;9:177 85. S7.4-33. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299 302. S7.4-34. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age- dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a compre- hensive outpatient perspective.


Prevalence and age- dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a compre- hensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042 8. S7.4-35. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta- analysis of genotype-phenotype associations in patients with hyper- trophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800 11. S7.4-36. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopa- thy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:783 831. S7.4-37. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gado- linium enhancement in clinical outcomes for hypertrophic cardio- myopathy. JACC Cardiovasc Imaging. 2012;5:370 7. S7.4-38. O Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867 74. S7.4-39. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast- enhanced magnetic resonance imaging in patients with hypertro- phic cardiomyopathy. Circ Heart Fail. 2010;3:51 8. S7.4-40. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratifica- tion and management. J Am Coll Cardiol. 2017;69:761 73. S7.4-41. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127:585 93. S7.4-42. Francia P, Adduci C, Palano F, et al. Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.


Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:893 9. CLINICAL STATEMENTS AND GUIDELINES S7.4-43. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161 70. S7.4-44. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899 908. S7.4-45. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248 57. S7.4-46. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31:1551 3. S7.4-47. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107:604 8. S7.4-48. Ingles J, Doolan A, Chiu C, et al. Compound and double muta- tions in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59. S7.4-49. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753 60. S7.4-50. O Mahony C, Jichi F, Monserrat L, et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricu- lar wall thickness in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e003818. S7.4-51. Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro- physiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758 62. S7.4-52. Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene but many phenotypes. Am J Cardiol.


Hypertrophic cardiomyopathy: one gene but many phenotypes. Am J Cardiol. 2014;113:1772 3. S7.4-53. Ho CY, Cirino AL, Lakdawala NK, et al. Evolution of hypertro- phic cardiomyopathy in sarcomere mutation carriers. Heart. 2016;102:1805 12. S7.4-54. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardio- vascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561 7. S7.4-55. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertro- phic cardiomyopathy. Circulation. 2008;118:1541 9. S7.4-56. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of mid- ventricular obstruction in patients with hypertrophic cardiomyopa- thy. J Am Coll Cardiol. 2011;57:2346 55. S7.5-1. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term progno- sis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133 44. S7.5-2. Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115:1733 8. S7.5-3. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860 6. S7.5-4. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15 22. S7.5-5. Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infec- tious myocarditis, lymphocytic myocarditis and dilated cardiomy- opathy. Eur Heart J. 1995:16 suppl O:36 41. S7.5-6. Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25:279 85. S7.5-7. Winkel E, Parrillo J. Myocarditis. Curr Treat Options.


2000;25:279 85. S7.5-7. Winkel E, Parrillo J. Myocarditis. Curr Treat Options. Cardiovasc Med. 2002;4:455 66. S7.5-8. Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21:1378 84. S7.5-9. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl- edge on aetiology, diagnosis, management, and therapy of myo- carditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636 2648d. S7.5-10. Elamm C, Fairweather D, Cooper LT, Pathogenesis and diagnosis of myocarditis. Heart. 2012;98:835 40. S7.5-11. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738 47. S7.5-12. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term out- come of fulminant myocarditis as compared with acute (nonfulmi- nant) myocarditis. N Engl J Med. 2000;342:690 5. S7.5-13. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091 100. S7.5-14. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639 48. S7.5-15. Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia asso- ciated with Coxsackie B4 virus infection. Acta Paediatr Scand. 1990;79:572 5. S7.5-16. Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachy- cardia complicating acute coxsackie B myocarditis. Cardiology. 1992;80:339 44. S7.5-17. Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc. 1987;85:336 7. S7.5-18. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.


ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803 69. S7.5-19. Cooper LT Jr, Elamm C, Giant cell myocarditis. Diagnosis and treat- ment. Herz. 2012;37:632 6. S7.5-20. Milei J, Grana D, Fernandez AG, et al. Cardiac involvement in acquired immunodeficiency syndrome a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clin Cardiol. 1998;21:465 72. S7.5-21. Yunis NA, Stone VE, Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:145 54. S7.5-22. Huang CN, Yu HH, Chiu SN, et al. Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythe- matosus. Rheumatol Int. 2013;33:1093 6. S7.5-23. Rassi A Jr, Rassi A, Little WC, Chagas heart disease. Clin Cardiol. 2000;23:883 9. S7.5-24. Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas disease: are they different from patients with coronary disease? Pacing Clin Electrophysiol. 1997;20:194 7. S7.5-25. d Avila A, Splinter R, Svenson RH, et al. New perspectives on cath- eter-based ablation of ventricular tachycardia complicating Chagas disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas VT. J Interv Card Electrophysiol. 2002;7:23 38. S7.5-26. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.5-27. Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD.


Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27:4 9. S7.5-28. Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med. 2001;3:463 7. 7.6. Cardiac Sarcoidosis S7.6-1. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epi- demiology, characteristics, and outcome over 25 years in a nation- wide study. Circulation. 2015;131:624 32. S7.6-2. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long- term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006 10. S7.6-3. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implant- able cardiac defibrillators for treatment of ventricular arrhyth- mias in patients with cardiac sarcoidosis. Europace. 2013;15: 347 54. CLINICAL STATEMENTS AND GUIDELINES S7.6-4. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electro- physiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014;25:171 6. S7.6-5. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defi- brillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925 9. S7.6-6. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411 20. S7.6-7. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial dam- age in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738. S7.6-8. Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imag- ing for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhyth- mias. Circ Arrhythm Electrophysiol. 2014;7:1109 15. S7.6-9.


Magnetic resonance imag- ing for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhyth- mias. Circ Arrhythm Electrophysiol. 2014;7:1109 15. S7.6-9. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501 11. S7.6-10. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with sus- pected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329 36. S7.6-11. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ven- tricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276 82. S7.6-12. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779 89. S7.6-13. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of car- diac sarcoidosis. Am J Cardiol. 2015;115:505 9. S7.6-14. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407 13. S7.6-15. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e003353. S7.6-16. Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140 7. S7.6-17. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus state- ment on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305 23. S7.6-18. Mehta D, Mori N, Goldbarg SH, et al.


2014;11:1305 23. S7.6-18. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sud- den cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43 8. 7.6.1. Other Infiltrative Cardiomyopathies S7.6.1-1. Lubitz SA, Goldbarg SH, Mehta D, Sudden cardiac death in infiltra- tive cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hema- chromatosis. Prog Cardiovasc Dis. 2008;51:58 73. S7.6.1-2. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implanta- tion of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235 40. S7.6.1-3. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemother- apy for light-chain amyloidosis in patients presenting with symp- tomatic heart failure. J Am Coll Cardiol. 2016;67:2941 8. S7.6.1-4. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter- defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11:158 62. 7.7. Heart Failure 7.7.1. HF With Reduced Ejection Fraction S7.7.1-1. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158 65. S7.7.1-2. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.7.1-3. Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrilla- tor as a bridge to cardiac transplantation: a national database analy- sis. J Heart Lung Transplant. 2015;34:1305 49. S7.7.1-4. Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation. 2001;104:171 6. S7.7.1-5. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio- verter-defibrillators on waitlist mortality among patients await- ing heart transplantation. An UNOS/OPTN Analysis. JACC Clin Electrophysiol. 2017;3:33 40. S7.7.1-6. Packer DL, Prutkin JM, Hellkamp AS, et al.


2017;3:33 40. S7.7.1-6. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170 6. S7.7.1-7. MERIT-HF Study Effect of metoprolol CR/XL in chronic heart fail- ure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 7. S7.7.1-8. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675 80. S7.7.1-9. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classifica- tion. Eur Heart J. 1996;17:1390 403. S7.7.1-10. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients characteristics: a meta-analysis of clinical tri- als. Arch Intern Med. 2000;160:621 7. S7.7.1-11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldoste- rone blocker, in patients with left ventricular dysfunction after myo- cardial infarction. N Engl J Med. 2003;348:1309 21. S7.7.1-12. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin- receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990 7. S7.7.1-13. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539 4. S7.7.1-14. Tomaselli GF, Zipes DP, What causes sudden death in heart failure? Circ Res. 2004;95:754 63. S7.7.1-15. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97:155 60. S7.7.1-16. Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart.


Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart. J Physiol. 2016;594:3963 80. S7.7.1-17. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter- defibrillator use in patients with left ventricular assist devices: a sys- tematic review and meta-analysis. JACC Heart Fail. 2016;4:772 9. 7.7.2. HF With Preserved Ejection Fraction S7.7.2-1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S7.7.2-2. Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18:749 54. S7.7.2-3. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S7.7.2-4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesar- tan in patients with chronic heart failure and preserved left- ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S7.7.2-5. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370: 1383 92. S7.7.2-6. Al-Khatib SM, Shaw LK, O Connor C, et al. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231 5. S7.7.2-7. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac- tion in tetralogy of Fallot. QRS prolongation relates to right ventricu- lar size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231 7. CLINICAL STATEMENTS AND GUIDELINES S7.7.2-8. Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of pro- grammed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol. 2014;176:1449 51. 7.7.3. Left Ventricular Assist Device S7.7.3-1.


Int J Cardiol. 2014;176:1449 51. 7.7.3. Left Ventricular Assist Device S7.7.3-1. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter- defibrillator use in patients with left ventricular assist devices: a sys- tematic review and meta-analysis. JACC Heart Fail. 2016;4:772 9. S7.7.3-2. Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010;7:466 71. S7.7.3-3. Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after contin- uous-flow left ventricular assist device implantation. Am Heart J. 2012;164:373 8. S7.7.3-4. Garan AR, Yuzefpolskaya M, Colombo PC, et al. Ventricular arrhyth- mias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol. 2013;61:2542 50. S7.7.3-5. Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implant- able cardioverter-defibrillators in left ventricular assist device-sup- ported heart failure patients. J Card Fail. 2012;18:140 5. S7.7.3-6. Enriquez AD, Calenda B, Miller MA, et al. The role of implantable cardioverter-defibrillators in patients with continuous flow left ven- tricular assist devices. Circ Arrhythm Electrophysiol. 2013;6:668 74. S7.7.3-7. Lee W, Tay A, Subbiah RN, et al. Impact of implantable cardioverter defibrillators on survival of patients with centrifugal left ventricular assist devices. Pacing Clin Electrophysiol. 2015;38:925 33. S7.7.3-8. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destina- tion therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospec- tive study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751 7. S7.7.3-9. Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ven- tricular assist devices: patient selection and outcomes. Curr Opin Cardiol. 2011;26:232 6. 7.7.4. ICD Use After Heart Transplantation S7.7.4-1.


Curr Opin Cardiol. 2011;26:232 6. 7.7.4. ICD Use After Heart Transplantation S7.7.4-1. Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable car- dioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197 201. S7.7.4-2. McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847 50. S7.7.4-3. Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defi- brillators in a heart transplant population: A single-center experi- ence. J Heart Lung Transplant. 2016;35:682 4. S7.7.4-4. Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and tem- poral trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684 90. S7.7.4-5. Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503 9. 7.8. Neuromuscular Disorders S7.8-1. Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ven- tricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160:1137 41, 41. S7.8-2. Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implica- tions for catheter ablation. Circulation. 1998;98:541 6. S7.8-3. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.8-4. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. S7.8-5. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.8-6. Pasotti M, Klersy C, Pilotto A, et al.


2006;354:209 10. S7.8-6. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.8-7. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.8-8. Russo V, Nigro G. ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial func- tion: 2013 ESC guidelines on cardiac pacing and cardiac resynchro- nization therapy. Europace. 2015;17:337. S7.8-9. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormali- ties and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688 97. S7.8-10. Lallemand B, Clementy N, Bernard-Brunet A, et al. The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications. Heart. 2012;98:291 6. S7.8-11. Nazarian S, Wagner KR, Caffo BS, et al. Clinical predictors of con- duction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol. 2011;34:171 6. S7.8-12. Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dys- function and conduction disturbances in patients with myotonic muscular dystrophy type I and II. JAMA Cardiology. 2017;2:225 8. S7.8-13. Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardio- verter-defibrillator use in a US myotonic dystrophy type 1 popula- tion. J Cardiovasc Electrophysiol. 2011;22:1369 75. S7.8-14. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150:54 8. S7.8-15. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890 5. S7.8-16. Epstein AE, DiMarco JP, Ellenbogen KA, et al.


2012;9:1890 5. S7.8-16. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormali- ties: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350 408. S7.8-17. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhyth- mic and nonarrhythmic outcomes of lamin A/C mutation carriers. Circulation. 2008;117:e350 408. S7.8-18. Brembilla-Perrot B, Luporsi JD, Louis S, et al. Long-term follow-up of patients with myotonic dystrophy: an electrocardiogram every year is not necessary. Europace. 2011;13:251 7. S7.8-19. Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio- ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II Pacing. Clin Electrophysiol. 2012;35:1262 9. 7.9. Cardiac Channelopathies S7.9-1. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6 15. S7.9-2. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syn- drome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S7.9-3. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher- ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S7.9-4. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37 45. S7.9-5. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S7.9-6.


Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S7.9-6. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872 82. CLINICAL STATEMENTS AND GUIDELINES S7.9-7. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. S7.9-8. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616 23. S7.9-9. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337 41. S7.9-10. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defi- brillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005;2:497 504. S7.9-11. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426 34. S7.9-12. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577 83. S7.9-13. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121:635 43. S7.9-14. Delise P, Allocca G, Marras E, et al. Risk stratification in individu- als with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32:169 76. S7.9-15. Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati- fication of young adults with Brugada syndrome. J Electrocardiol. 2013;46:279 83. S7.9-16. Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm.


Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm. 2008;5:831 6. S7.9-17. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation. 2001;104:557 62. S7.9-18. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342 7. S7.9-19. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syn- drome. JAMA. 2006;296:1249 54. S7.9-20. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta- blockers. JAMA. 2004;292:1341 4. S7.9-21. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S7.9-22. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol. 2009;54:832 7. S7.9-23. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. S7.9-24. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60000 exomes and ACMG guidelines question the role of catecholamin- ergic polymorphic ventricular tachycardia-associated variants. Clin Genet. 2017;91:63 72. S7.9-25. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587 95. S7.9-26. Mahida S, Derval N, Sacher F, et al. Role of electrophysiological stud- ies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015;65:151 9. S7.9-27. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natu- ral history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300 8. S7.9-28. Siebermair J, Sinner MF, Beckmann BM, et al.


2014;63:1300 8. S7.9-28. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolarization pat- tern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace. 2016;18:718 25. S7.9-29. Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol. 2007;50:1335 40. S7.9-30. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-cen- ter experience. Heart Rhythm. 2010;7:1616 22. S7.9-31. Proclemer A, Ghidina M, Facchin D, et al. Use of implantable cardio- verter-defibrillator in inherited arrhythmogenic diseases: data from Italian ICD Registry for the years 2001 6. Pacing Clin Electrophysiol. 2009;32:434 45. S7.9-32. Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe- cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. 2016;9:e003440. S7.9-33. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi- brillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879 88. S7.9-34. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443 54. S7.9-35. Rodriguez-Manero M, Sacher F, de Asmundis C, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13:669 82. S7.9-36. Rosso R, Glick A, Glikson M, et al. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J. 2008;10:435 9. S7.9-37. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9-38.


Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9-38. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adren- ergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9-39. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524 9. S7.9-40. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. 7.9.1. Specific Cardiac Channelopathy Syndromes 7.9.1.1. Congenital Long QT Syndrome S7.9.1.1-1. Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of differ- ent beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014;64:1352 8. S7.9.1.1-2. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol. 2010;21:893 901. S7.9.1.1-3. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limita- tions of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616 23. S7.9.1.1-4. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329 37. S7.9.1.1-5. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. S7.9.1.1-6. Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for congeni- tal long-qt syndrome type III: experimental and long-term clinical data. Circ Arrhythm Electrophysiol. 2016;9:e004370. S7.9.1.1-7. Chorin E, Taub R, Medina A, et al.


2016;9:e004370. S7.9.1.1-7. Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. Europace. 2017 euw439 [Epub ahead of print]. S7.9.1.1-8. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006;296:1249 54. S7.9.1.1-9. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783 8. S7.9.1.1-10. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053 8. S7.9.1.1-11. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S7.9.1.1-12. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolonga- tion and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.1-13. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and cate- cholaminergic polymorphic ventricular tachycardia using video- assisted thoracic surgery. Heart Rhythm. 2009;6:752 9. S7.9.1.1-14. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404 9. S7.9.1.1-15. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym- pathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catechol- aminergic polymorphic ventricular tachycardia and long QT syn- drome. Clin Res Cardiol. 2013;102:33 42. S7.9.1.1-16. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826 33. S7.9.1.1-17.


Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826 33. S7.9.1.1-17. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6 15. S7.9.1.1-18. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012;9:892 8. S7.9.1.1-19. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm. 2010;7:1797 805. S7.9.1.1-20. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender- specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011;8:1537 43. S7.9.1.1-21. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006;47:764 8. S7.9.1.1-22. Adler A, van der Werf C, Postema PG, et al. The phenomenon of QT stunning : The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9:901 8. S7.9.1.1-23. Aziz PF, Wieand TS, Ganley J, et al. Genotype- and mutation site-specific QT adaptation during exercise, recovery, and pos- tural changes in children with long-QT syndrome. Circ Arrhythm Electrophysiol. 2011;4:867 73. S7.9.1.1-24. Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocar- diogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 2010;7:906 11. S7.9.1.1-25. Laksman ZW, Hamilton RM, Chockalingam P, et al.


2010;7:906 11. S7.9.1.1-25. Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation loca- tion effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop loca- tion. J Cardiovasc Electrophysiol. 2013;24:1015 20. S7.9.1.1-26. Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol. 2011;32:63 6. S7.9.1.1-27. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187 94. S7.9.1.1-28. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syn- drome. Eur Heart J. 2004;25:1405 11. S7.9.1.1-29. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bed- side test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955 61. S7.9.1.1-30. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341 4. S7.9.1.1-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S7.9.1.1-32. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149 54. S7.9.1.1-33. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syn- drome. Pharmacol Rev. 2010;62:760 81. S7.9.1.1-34. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039 44. S7.9.1.1-35. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74.


Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S7.9.1.1-36. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872 82. S7.9.1.1-37. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113 20. S7.9.1.1-38. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866 72. S7.9.1.1-39. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recom- mendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437 45. S7.9.1.1-40. Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016;47:163 70. S7.9.1.1-41. Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-block- ers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60:2092 9. S7.9.1.1-42. Khositseth A, Tester DJ, Will ML, et al. Identification of a com- mon genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1: 60 4. S7.9.1.1-43. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syn- drome. LQTS Investigators. Circulation. 1998;97:451 6. S7.9.1.1-44. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9.1.1-45. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta- adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9.1.1-46. Moss AJ, Liu JE, Gottlieb S, et al.


1992;20:830 7. S7.9.1.1-46. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. CIRCULATION. 1991;84:1524 9. S7.9.1.1-47. Viskin S, Glikson M, Fish R, et al. Rate smoothing with car- diac pacing for preventing torsade de pointes. Am J Cardiol. 2000;86:111k 5k. S7.9.1.1-48. Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonre- sponders. Circ Arrhythm Electrophysiol. 2013;6:705 11. S7.9.1.1-49. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachy- cardia. N Engl J Med. 2008;358:2024 9. S7.9.1.1-50. Li J, Liu Y, Yang F, et al. Video-assisted thoracoscopic left car- diac sympathetic denervation: a reliable minimally invasive approach for congenital long-QT syndrome. Ann Thorac Surg. 2008;86:1955 8. S7.9.1.1-51. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage- ment of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131:2185 93. S7.9.1.1-52. Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic dener- vation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20:137 41. S7.9.1.1-53. Burns C, Ingles J, Davis AM, et al. Clinical and genetic features of Australian families with long QT syndrome: a registry based study. J Arrhythm. 2016;32:456 61. S7.9.1.1-54. Barsheshet A, Goldenberg I, Uchi J, et al. Mutations in cyto- plasmic loops of the KCNQ1 channel and the risk of life-threat- ening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988 96. S7.9.1.1-55. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clini- cal manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366 75. S7.9.1.1-56.


The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clini- cal manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366 75. S7.9.1.1-56. Zhang C, Kutyifa V, McNitt S, et al. Identification of low-risk adult congenital LQTS patients. J Cardiovasc Electrophysiol. 2015;26:853 8. S7.9.1.1-57. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharma- cological treatment. J Am Coll Cardiol. 2004;43:1494 9. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.1-58. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol. 2009;54:832 7. S7.9.1.1-59. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. S7.9.1.1-60. Rohatgi RK, Bos JM, Ackerman MJ. Stimulant therapy in chil- dren with attention-deficit/hyperactivity disorder and concomi- tant long QT syndrome: a safe combination? Heart Rhythm. 2015;12:1807 12. S7.9.1.1-61. Amin AS, Klemens CA, Verkerk AO, et al. Fever-triggered ven- tricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J. 2010;18:165 9. S7.9.1.1-62. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013 22. 7.9.1.2. Catecholaminergic Polymorphic Ventricular Tachycardia S7.9.1.2-1. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricu- lar tachycardia. Circulation. 2009;119:2426 34. S7.9.1.2-2. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of thera- peutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8:633 42. S7.9.1.2-3. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and cate- cholaminergic polymorphic ventricular tachycardia using video- assisted thoracic surgery. Heart Rhythm. 2009;6:752 9. S7.9.1.2-4. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias.


Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404 9. S7.9.1.2-5. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym- pathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catechol- aminergic polymorphic ventricular tachycardia and long QT syn- drome. Clin Res Cardiol. 2013;102:33 42. S7.9.1.2-6. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244 5. S7.9.1.2-7. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S7.9.1.2-8. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymor- phic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512 9. S7.9.1.2-9. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel block- ers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149 54. S7.9.1.2-10. Swan H, Laitinen P, Kontula K, et al. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catechol- aminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:162 6. S7.9.1.2-11. Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recur- rences in genotype-negative patients with catecholaminergic poly- morphic ventricular tachycardia. Heart Rhythm. 2013;10:542 7. S7.9.1.2-12. Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhyth- mic drugs in catecholaminergic polymorphic ventricular tachycar- dia. Circ Arrhythm Electrophysiol. 2011;4:128 35. S7.9.1.2-13. Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe- cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. 2016;9:e003440. S7.9.1.2-14. Olde Nordkamp LR, Postema PG, Knops RE, et al.